Systemic Chemotherapy Is Modulated by Platelet-Activating Factor-Receptor Agonists
Chemotherapy is used to treat numerous cancers including melanoma. However, its effectiveness in clinical settings is often hampered by various mechanisms. Previous studies have demonstrated that prooxidative stressor-mediated generation of oxidized lipids with platelet-activating factor-receptor (P...
Saved in:
| Main Authors: | Ravi P. Sahu, Matheus Ferracini, Jeffrey B. Travers |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2015/820543 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of targeting the platelet-activating factor and its receptor in cancer treatment
by: Kimya Qaderi, et al.
Published: (2025-03-01) -
Clearance of Apoptotic Cells by Macrophages Induces Regulatory Phenotype and Involves Stimulation of CD36 and Platelet-Activating Factor Receptor
by: Matheus Ferracini, et al.
Published: (2013-01-01) -
Observation on the efficacy of TPO receptor agonists and platelet transfusion in chemotherapy-induced thrombocytopenia in malignant tumors
by: Huan Hu, et al.
Published: (2025-01-01) -
Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?
by: Hanny Al-Samkari
Published: (2025-07-01) -
Modulation of Tumor-Associated Macrophages (TAM) Phenotype by Platelet-Activating Factor (PAF) Receptor
by: Ildefonso Alves da Silva Junior, et al.
Published: (2017-01-01)